日久光電(003015.SZ):目前公司的OCA光學膠以消費電子應用為主
格隆匯4月21日丨有投資者在投資者互動平台向日久光電(003015.SZ)提問,“公司的OCA 光學膠 能用在集成電路上嗎”
日久光電回覆稱,暫時未應用在集成電路。目前公司的OCA光學膠以消費電子應用為主,該產品為無基體材料的雙面貼合膠帶,是觸摸屏集成用的關鍵材料之一,分為蓋板和觸摸屏、膜與膜之間的薄型框貼OCA產品以及觸摸屏和液晶模組之間的全貼合產品兩種。同時,公司配套光學膜產品進行耐摺疊OCA光學膠和曲面OCA光學膠的研發並取得了積極進展。其中耐摺疊OCA光學膠已完成了前期開發及工藝驗證,客户端認證樣品過程中,曲面OCA光學膠已完成了試量產,客户端認證量產樣品過程中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.